Achaogen (AKAO) Reaches $21.79 After 8.00% Up Move, Lemaitre Vascular Has 1.12 Sentiment

June 13, 2017 - By Peter Erickson

The stock of Achaogen Inc (NASDAQ:AKAO) is a huge mover today! About 132,051 shares traded. Achaogen Inc (NASDAQ:AKAO) has risen 757.99% since June 13, 2016 and is uptrending. It has outperformed by 741.29% the S&P500.The move comes after 5 months positive chart setup for the $852.79M company. It was reported on Jun, 13 by Barchart.com. We have $23.53 PT which if reached, will make NASDAQ:AKAO worth $68.22 million more.

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The company has market cap of $522.58 million. The Firm develops, makes and markets medical devices and implants used primarily in the field of vascular surgery. It has a 48.52 P/E ratio. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Since January 1, 0001, it had 0 insider buys, and 9 insider sales for $8.92 million activity.

Awm Investment Company Inc. holds 3.8% of its portfolio in LeMaitre Vascular Inc for 765,105 shares. First Light Asset Management Llc owns 159,943 shares or 1.78% of their US portfolio. Moreover, Grandeur Peak Global Advisors Llc has 0.72% invested in the company for 155,827 shares. The Maryland-based Campbell & Co Investment Adviser Llc has invested 0.63% in the stock. Continental Advisors Llc, a Illinois-based fund reported 84,900 shares.

About 31,645 shares traded. LeMaitre Vascular Inc (LMAT) has risen 101.07% since June 13, 2016 and is uptrending. It has outperformed by 84.37% the S&P500.

Analysts await LeMaitre Vascular Inc (NASDAQ:LMAT) to report earnings on July, 26. They expect $0.17 earnings per share, up 21.43% or $0.03 from last year’s $0.14 per share. LMAT’s profit will be $3.05 million for 42.82 P/E if the $0.17 EPS becomes a reality. After $0.16 actual earnings per share reported by LeMaitre Vascular Inc for the previous quarter, Wall Street now forecasts 6.25% EPS growth.

Ratings analysis reveals 0 of Lemaitre Vascular’s analysts are positive. Out of 2 Wall Street analysts rating Lemaitre Vascular, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. LMAT was included in 2 notes of analysts from September 22, 2016. The firm earned “Neutral” rating on Thursday, September 22 by Sidoti. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) earned “Mkt Perform” rating by Barrington Research on Wednesday, February 22.

Since December 19, 2016, it had 11 buys, and 10 selling transactions for $74.00 million activity. Schilke Tobin sold 955 shares worth $16,025. Another trade for 500,000 shares valued at $6.75M was made by SANDELL SCOTT D on Monday, December 19. Hillan Kenneth J. sold $38,601 worth of stock or 1,696 shares. Sonsini Peter W. had bought 500,000 shares worth $6.75M on Monday, December 19. Shares for $6.75M were bought by Viswanathan Ravi on Monday, December 19. $11,662 worth of stock was sold by Friedland Ian on Thursday, January 26. $6.75M worth of Achaogen Inc (NASDAQ:AKAO) shares were bought by BASKETT FOREST.

Among 7 analysts covering Achaogen (NASDAQ:AKAO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Achaogen had 11 analyst reports since March 16, 2016 according to SRatingsIntel. The stock has “Outperform” rating by Wedbush on Tuesday, June 14. The firm earned “Buy” rating on Wednesday, November 2 by Aegis Capital. The rating was downgraded by Needham to “Hold” on Wednesday, March 16. On Wednesday, February 1 the stock rating was maintained by Wedbush with “Outperform”. The firm earned “Buy” rating on Tuesday, December 13 by Needham. On Wednesday, January 4 the stock rating was initiated by Leerink Swann with “Outperform”. The stock of Achaogen Inc (NASDAQ:AKAO) has “Buy” rating given on Thursday, June 1 by Cowen & Co. The stock of Achaogen Inc (NASDAQ:AKAO) earned “Outperform” rating by Cowen & Co on Monday, November 28. The stock of Achaogen Inc (NASDAQ:AKAO) earned “Buy” rating by Stifel Nicolaus on Tuesday, February 7. The firm earned “Market Perform” rating on Thursday, March 31 by Cowen & Co.

Achaogen, Inc. is a late-stage biopharmaceutical company. The company has market cap of $852.79 million. The Firm is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant gram-negative infections. It currently has negative earnings. The Firm is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Investors sentiment increased to 3.19 in 2016 Q4. Its up 2.12, from 1.07 in 2016Q3. It improved, as 7 investors sold Achaogen Inc shares while 9 reduced holdings. 39 funds opened positions while 12 raised stakes. 44.90 million shares or 227.11% more from 13.73 million shares in 2016Q3 were reported. Eam Ltd Llc stated it has 432,715 shares. Israel-based Sphera Funds Management Limited has invested 1.7% in Achaogen Inc (NASDAQ:AKAO). Columbia Pacific Advisors Ltd Co holds 0.4% in Achaogen Inc (NASDAQ:AKAO) or 55,000 shares. 33,866 were accumulated by Northern Tru. Spark Mgmt Ltd Liability Com holds 99,700 shares or 0.11% of its portfolio. Citadel Advisors Ltd Liability invested 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO). Gabelli Funds Ltd owns 61,800 shares. Nea Management Lc invested 2.7% in Achaogen Inc (NASDAQ:AKAO). Voloridge Investment Mngmt Ltd Llc stated it has 0% in Achaogen Inc (NASDAQ:AKAO). 20,000 are held by Weiss Multi. Ballentine Limited Liability Company reported 19,823 shares or 0.02% of all its holdings. Ellington Management Gru Limited Liability holds 0.06% or 30,000 shares. State Street, a Massachusetts-based fund reported 18,600 shares. Fmr Ltd Liability owns 2.91 million shares or 0.01% of their US portfolio. Iconiq Limited Liability Company invested 0.04% of its portfolio in Achaogen Inc (NASDAQ:AKAO).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.